HD Insights™

HD INSIGHTS TM Clinical Trials Table SPONSOR National Institute of Neurological Disorders and Stroke National Center for Complementary and Alternative Medicine Assistance Publique - Hôpitaux de Paris Siena Biotech Olanzapine, Tetrabenazine and Tiapride Selisistat, SEN0014196 Novartis Pharmaceuticals National Institute of Neurological Disorders and Stroke Charite University Coenzyme Q10 II Christopher A. Ross, MD, PhD AFQ056 II II III Anne-Catherine Bachoud Levi, PhD STUDY AGENT Coenzyme Q10 PHASE III PRINCIPAL INVESTIGATOR Merit Cudkowicz, MD, MSc Randomized double blind study to see if coenzyme Q10 is effective in slowing the worsening of symptoms of Huntington disease Creatine III Steven M Hersch, MD, PhD Randomized double blind study to test whether high-dose creatine can slow the progressive functional decline that occurs in adult persons with early clinical features of Huntington disease Randomized controlled study to compare the beneficial and adverse effects of 3 different neuroleptics in Huntington disease Ralf Reilmann, MD Randomized, double blind, placebo-controlled parallel-group design at two dose levels of SEN0014196 in early-stage Huntington disease patients Ralf Reilmann, MD Randomized double blind study of the efficency, safety, and tolerability of AFQ056 in reducing Chorea Randomized double blind study testing the tolerability of treatment with 600, 1200 or 2400 mg per day of coenzyme Q10 in pre-manifest participants carrying the CAGn expansion for Huntington disease Epigallo- catechin Gallate Neurosearch A/S Pridopidine II Josef Priller, MD Randomized double blind study testing the efficacy and tolerability of (2)- epigallocatechin-3-gallate (EGCG) in changing cognitive function in patients with Huntington disease II Karl Kieburtz, MD MPH National Institute of Neurological Disorders and Stroke National Institutes of Health Siena Biotech Selisistat, SEN0014196 Siena Biotech Selisistat, SEN0014196 I Bernhard Landwehrmeyer, MD I Citalopram II Leigh J Beglinger, PhD Open label, single group assignment study to assess the long-term safety of 45 mg of pridopidine in Huntington disease participants Randomized double blind study of the effect of Citalopram on tolerability, functional measures, motor performance, and psychiatric status Creatine II Diana Rosas, MD, MS Open label, single group assignment study to further assess the long-term safety and tolerability of up to 30 grams of creatine daily in Huntington disease participants Francis Walker, MD Open-label, randomized, parallel group design at one dose level of SEN0014196 in early stage Huntington disease patients Randomized, double blind, placebo controlled parallel group design at two dose levels of SEN0014196 in early-stage Huntington disease patients 8 **All studies are currently enrolling, unless otherwise noted Copyright © Huntington Study Group 2011. All rights reserved. Sources: www.clinicaltrials.gov and World Health Organization HD InsightsTM, Vol. 1 14 days 12 months 2 years 22 total - U.S. and Canada 16 weeks 3 total - United States 1 total - United States 6 total - United States 14 days 6 total - Europe N/A Ongoing Blair Harrison, MPH: 319-353-4411 Open until Dec '11 N/A Ongoing, recruitment complete Goran Westerberg,PhD: gwesterberg@ sienabiotech.it Goran Westerberg,PhD: gwesterberg@ sienabiotech.it 46 days 20 weeks 10 total - Europe 13 total - United States 1 year 3 total - Europe 1 year DESIGN TRIAL LENGTH 5 years SITES CONTACT/ STATUS 47 total - U.S., Canada, Australia 3 years 60 total - U.S., Canada, Australia, New Zealand Huntington Study Group: 800-487-7671 Huntington Study Group: 800-487-7671 1 total - Europe 3 months 18 total - Europe Bachoud-Levi Anne-Catherine, PhD: +33 (0)1 49 81 23 01 Goran Westerberg, PhD: gwesterberg@ sienabiotech.it Novartis: +41 61 324 1111 Elaine M Julian- Baros, BS: 585-273-2879 Enrollment Complete N/A

• Cover